Deoxyribonuclease I (Nickase)

An enzyme capable of hydrolyzing highly polymerized DNA by splitting phosphodiester linkages, preferentially adjacent to a pyrimidine nucleotide. This catalyzes endonucleolytic cleavage of DNA yielding 5'-phosphodi- and oligonucleotide end-products. The enzyme has a preference for double-stranded DNA.

Also Known As:

Nickase; Streptodornase; DNase I; DNA Endonuclease; DNA Nicking Enzyme; DNAase I; Dornavac; Endonuclease I; Pancreatic DNase; T4-Endonuclease II; T7-Endonuclease I; Thymonuclease; DNase, Pancreatic; Endonuclease, DNA; T4 Endonuclease II; T7 Endonuclease I

Networked: 1357 relevant articles (36 outcomes, 104 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Hydrolases: 2166
    - Esterases: 1574
      - Deoxyribonucleases: 1259
        Endodeoxyribonucleases
        Deoxyribonuclease I: 1357
        dornase alfa: 387
        Streptodornase and Streptokinase: 145
        E coli BspD6I protein
        human DNASE1 protein
        human DNASE1L1 protein
        human DNASE1L2 protein
        human LINE-1 endonuclease
        rat DNASE1L3 protein
        Streptococcus pyogenes Sda1 protein

Experts

1.	Yasuda, Toshihiro: 23 articles (10/2019 - 05/2004)
2.	Takeshita, Haruo: 16 articles (10/2019 - 01/2006)
3.	Fujihara, Junko: 14 articles (10/2019 - 01/2006)
4.	Kawai, Yasuyuki: 14 articles (01/2019 - 05/2004)
5.	Ueki, Misuzu: 13 articles (10/2019 - 07/2005)
6.	Stamatoyannopoulos, John A: 12 articles (01/2022 - 03/2011)
7.	Iida, Reiko: 11 articles (01/2019 - 07/2006)
8.	Kominato, Yoshihiko: 10 articles (01/2014 - 11/2005)
9.	Kimura-Kataoka, Kaori: 7 articles (10/2019 - 07/2010)
10.	Nakajima, Tamiko: 7 articles (01/2014 - 07/2006)

Related Diseases

1.	Hypersensitivity (Allergy) 07/01/2017 - "Previously, DNase I hypersensitivity sites were reported to explain 79% of SNP heritability; using our improved heritability model, their estimated contribution is only 24%." 08/25/2000 - "To locate liver-specific elements in other segments of the human gene, DNase I hypersensitivity studies were performed with transcriptionally active, liver-derived HepG2 cells and with transcriptionally inactive HeLa cells. " 10/17/1996 - "DNase I hypersensitivity studies showed increased DNase I resistance and the loss of a hypersensitive site in differentiated F9 cells. " 05/13/1994 - "In order to localize the critical regulatory elements important for tissue-specific, high level WAP gene expression, DNase I hypersensitivity mapping studies of WAP transgenes were performed in nuclei isolated from mammary gland and liver. " 08/01/1993 - "We have chosen to use the approaches involving in situ nick translation and have shown that the patterns of DNase I hypersensitivity and of CpG islands on human chromosomes show a strict correspondence to R-banding patterns: Deviations from R-banding patterns reported by previous investigators who have made similar studies appear to be attributable to excessive digestion.(ABSTRACT TRUNCATED AT 250 WORDS)"
2.	Neoplasms (Cancer) 02/01/2007 - "The use of DNAse I pre-treatment significantly increases the reliability and sensitivity of immunodetection of CKI nuclear factors, and should be useful for both developmental neurobiology studies as well as cancer diagnostic applications." 01/01/2022 - "Besides, it neutralizes tumor acidity to reduce tumor infiltration of immunosuppressive cells, and releases DNase I in a pH-responsive manner to degrade NETs. " 12/22/2021 - "After accumulating at the site of the tumor tissue, the nanocarrier can release DNase I in response to MMP-9 to degrade the structure of NETs. " 12/01/2021 - "DNase I-assisted 2'-O-methyl molecular beacon for amplified detection of tumor exosomal microRNA-21." 10/23/2021 - "Remarkably, DNase I decreases tumor-associated neutrophils and the formation of MC38 tumor cell-induced neutrophil extracellular trap formation in vivo. "
3.	Cystic Fibrosis (Mucoviscidosis) 04/01/2001 - "Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions." 11/01/2012 - "Moreover, as shown above, DNase I is utilized in the treatment of patients with cystic fibrosis. " 08/06/1996 - "Engineering actin-resistant human DNase I for treatment of cystic fibrosis." 01/01/2017 - "Human DNase I (hDNase I) is used therapeutically for the treatment of cystic fibrosis (CF) and may have potential benefit for use in systemic lupus erythematosus (SLE). " 07/17/1998 - "Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus."
4.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 08/01/2014 - "In the present study, we have extensively continued our previous investigations of the nonsynonymous single-nucleotide polymorphisms (SNPs) in the human DNase I (DNASE1) gene potentially relevant to systemic lupus erythematosus (SLE); therefore, all of the 58 nonsynonymous SNPs registered in the NCBI dbSNP database could be evaluated and it could be checked as to whether these SNPs might serve as a functional SNP. " 04/01/2007 - "Study of DNASE I gene polymorphisms in systemic lupus erythematosus susceptibility." 06/10/1973 - "[Studies on DNase I activity and its heat-labile inhibitor in systemic lupus erythematosus]." 02/10/1970 - "[Studies on Dnase I activity in systemic lupus erythematosus]." 04/01/2016 - "Using the Polymerase chain reaction restriction fragment length polymorphism method, the Q222R (+2373A→G; Gln244Arg) DNase I polymorphism was studied in 156 systemic lupus erythematosus patients and 170 healthy controls. "
5.	Infections 11/30/2023 - "More importantly, as an immune switchpoint regulator, DNase-I@V2 C can skew neutrophil functions from NETosis towards phagocytosis by intercepting ROS-NE/MPO-PAD4 and activating ROS-PI3K-AKT-mTOR pathways in diabetic microenvironment, thereby eliminating biofilm infections. " 01/01/2022 - "However, systemic biodistribution of DNase I raises safety issues, potentially impairing host defense against infection. " 03/31/2021 - "Therefore, DNase I coating could be an alternative approach for preventing implant-related infection." 01/01/2019 - "Treating WT mice with deoxyribonuclease I, which can disrupt NETs generation, recapitulated the exacerbated CR infection and gut pathology associated with the loss of PAD4. " 01/01/2019 - "Treatment with DNase I destroys root tip resistance to infection by fungi, the most abundant plant pathogens. "

Related Drugs and Biologics

1.	Streptokinase
2.	DNA (Deoxyribonucleic Acid)
3.	Deoxyribonuclease I (Nickase)
4.	Streptodornase and Streptokinase
5.	Anti-Bacterial Agents (Antibiotics)
6.	Hydrogels
7.	Chromatin
8.	Enzymes
9.	Proteins (Proteins, Gene)
10.	Deoxyribonucleases (DNase)

Related Therapies and Procedures

1.	Debridement
2.	Immunotherapy
3.	Therapeutics
4.	Intravenous Injections
5.	Nanospheres